Condensed Consolidated Statements of Operations [Abstract] | |
Net Sales | 47M |
COST OF SALES | 17.28M |
GROSS PROFIT | 29.72M |
OPERATING EXPENSES | |
Research and development | 3.76M |
Selling and marketing | 8.13M |
General and administrative | 7.98M |
European and global sales & marketing leadership reorganization | |
Bioline Group transaction costs | |
Total operating expenses | 20.83M |
OPERATING INCOME | 8.9M |
OTHER INCOME (EXPENSE) | |
Interest income | |
Other, net | 259K |
Total other income (expense) | -143K |
EARNINGS BEFORE INCOME TAXES | |
INCOME TAX PROVISION | 3.26M |
NET EARNINGS | |
BASIC EARNINGS PER COMMON SHARE | 0.13 |
DILUTED EARNINGS PER COMMON SHARE | 0.13 |
AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC | -84.07M |
EFFECT OF DILUTIVE STOCK OPTIONS | -756K |
AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - DILUTED | -84.82M |
ANTI-DILUTIVE SECURITIES: | |
Common share options | -897K |
DIVIDENDS DECLARED PER COMMON SHARE | 0.2 |